You Searched For "Heather Bresch" and got 20 results
Sort By:
1 min read
There's a shortage of EpiPens in the US
Mylan came under fire in 2016 for raising the price of the EpiPen to $608.61 from $93.88 over the p…
Lydia Ramsey
3 mins read
The CEO of EpiPen maker Mylan once claimed she had an MBA that she never earned
Soon after the accusations, the university commissioned a special panel to look into Bresch's degre…
Christina Sterbenz
2 mins read
The maker of EpiPen just made a big change to the story it told Congress last week
Representative Jason Chaffetz (R-UT) said he didn't feel like Bresch was "being honest" with the me…
Linette Lopez
3 mins read
The EpiPen maker's CEO knows who is responsible for soaring drug costs - and it's not her
The fury didn't end there. Her compensation became an issue, as did her parents' political connecti…
Lydia Ramsey
1 min read
LIVE: Mylan CEO Heather Bresch confronts a furious Congress about EpiPen's price hike
"Looking back, I wish we had better anticipated the magnitude and acceleration of the rising f…
Linette Lopez,Lydia Ramsey
1 min read
West Virginia has taken a huge shot at the maker of EpiPen
The CEO of Mylan, Heather Bresch, is the daughter of West Virginia Senator John Manchin. Obviously …
Linette Lopez
2 mins read
The EpiPen pricing scandal just got even more complicated for the CEO and her family at the heart of it
To fend off public outrage over the EpiPen's cost, Mylan recently raised its copay-coupon system to…
Lydia Ramsey
2 mins read
Elizabeth Warren had one question for the maker of EpiPen, and the CEO couldn't answer it at all
In Mylan's case, Warren wants a breakdown of: how many people have used Mylan's coupons and program…
Linette Lopez
1 min read
This free browser game is a hilarious satire of the EpiPen controversy
Things aren't looking so hot for Mylan CEO Heather Bresch these days. The pharmaceutical industry f…
Alex Perry
3 mins read
The numbers the maker of EpiPen just released expose yet another load of nonsense
"We didn't believe Mylan's numbers last week during their CEO's testimony, and we don't believe the…
Linette Lopez
1 min read
The maker of EpiPen has agreed to pay the government $465 million after overcharging for the medicine
Mylan had underpaid Medicare and Medicaid by classifying the EpiPen as a generic drug. Generic drug…
Bob Bryan
2 mins read
The EpiPen maker's CEO totally backs Trump on drug prices - except for how he plans to lower them
After getting called out for the $608 list price for a two-pack of EpiPens - an increase of about 5…
Lydia Ramsey
4 mins read
5 answers we got from the EpiPen hearing - and 5 things that just became more confusing
In 2014, when the list price was about $400, Bresch said the company got $235 from each two-pack, a…
Lydia Ramsey
3 mins read
The maker of EpiPen kept repeating one stat to Congress, and it's total nonsense
One explanation for this is that increasing drug prices and costs from medical suppliers have gotte…
Linette Lopez
3 mins read
2 questions EpiPen's maker desperately wants America to forget while it faces Congress
In a press release after Mylan announced a bunch of measures to help patients, Congressman Elijah C…
Linette Lopez
2 mins read
The $300 generic EpiPen is here
Authorized generics are basically a drugmaker's way of staying in the game after generic competitio…
Lydia Ramsey
3 mins read
Here's what to expect when the CEO of EpiPen-maker Mylan testifies before Congress
To fend off public outrage over the EpiPen's cost, Mylan recently raised its copay-coupon system to…
Lydia Ramsey
3 mins read
10 years ago, Mylan's CEO slammed the very thing her company just did
"For brand companies, authorized generics are a long-term strategy designed to debilitate our indus…
Lydia Ramsey
4 mins read
Here's why it's ridiculously tempting for the CEO of Mylan to keep hiking the price of EpiPen
Another way the company could get to $6 per share, is to increase EpiPen's 2015 sales - at the curr…
Linette Lopez
2 mins read
Advisers are telling investors to go scorched earth on the company that makes EpiPen
"The case for holding Mylan's entrenched Chairman and board accountable could not be stronger. The…